Autonomic Nervous System: Introduction

Correct Answer

C — Depolarizing neuromuscular blocking agent

Rationale

Succinylcholine is a depolarizing neuromuscular blocking agent — it activates nicotinic N-M receptors at the motor endplate, causing sustained depolarization that prevents muscle repolarization and produces flaccid paralysis. This distinguishes it from non-depolarizing agents such as rocuronium and vecuronium, which competitively block N-M receptors without depolarizing the endplate. Ganglionic blockers act at N-N receptors in autonomic ganglia, and muscarinic antagonists act at G-protein-coupled muscarinic receptors — neither mechanism describes succinylcholine.

Correct Answer

A — Irreversible non-selective alpha adrenergic receptor antagonist

Rationale

Phenoxybenzamine is an irreversible non-selective alpha adrenergic receptor antagonist — it binds covalently to both alpha-1 and alpha-2 receptors, producing blockade that cannot be overcome regardless of catecholamine concentration. This irreversibility is the key pharmacological feature distinguishing it from reversible competitive alpha-1 antagonists such as prazosin. The irreversible blockade makes phenoxybenzamine the preferred agent for preoperative management of pheochromocytoma. It is not a beta antagonist and does not block muscarinic receptors.

Correct Answer

D — Selective beta-1 adrenergic receptor agonist

Rationale

Dobutamine is a selective beta-1 adrenergic receptor agonist. It increases cardiac contractility and heart rate through beta-1 receptor stimulation and is used in acute decompensated heart failure and for cardiac stress testing. Its relative selectivity for beta-1 over beta-2 distinguishes it from isoproterenol, which is a non-selective beta agonist. A selective alpha-1 agonist such as phenylephrine produces vasoconstriction. A muscarinic agonist such as bethanechol produces parasympathetic effects.

Correct Answer

B — Inhaled muscarinic receptor antagonist

Rationale

Ipratropium is an inhaled muscarinic receptor antagonist. As a quaternary ammonium compound it is poorly absorbed from the airway into the systemic circulation, which limits its anticholinergic side effects to the local site of action. It blocks muscarinic M3 receptors in bronchial smooth muscle, preventing acetylcholine-mediated bronchoconstriction and producing bronchodilation. This mechanism distinguishes it from selective beta-2 agonists such as albuterol, which produce bronchodilation through adrenergic receptor activation. It is not an alpha-1 antagonist or an acetylcholinesterase inhibitor.

Correct Answer

C — Indirect-acting sympathomimetic

Rationale

Ephedrine is an indirect-acting sympathomimetic — it produces sympathomimetic effects primarily by entering sympathetic nerve terminals and promoting release of stored norepinephrine rather than by directly activating adrenergic receptors itself. It also has some direct agonist activity at adrenergic receptors, making it a mixed-acting agent, but its classification as an indirect-acting sympathomimetic captures its predominant mechanism. A direct-acting alpha-1 agonist such as phenylephrine acts exclusively at the receptor without entering the terminal. Ephedrine does not block muscarinic receptors and does not block ganglionic transmission.

Correct Answer

A — Reversible acetylcholinesterase inhibitor

Rationale

Neostigmine is a reversible acetylcholinesterase inhibitor — it inhibits the enzyme transiently through a carbamate linkage, with enzyme activity recovering over time. This reversibility distinguishes it from organophosphate inhibitors such as nerve agents and insecticides, which bind covalently and require pralidoxime for reactivation. Neostigmine does not block muscarinic receptors and does not block nicotinic receptors; instead, it enhances cholinergic transmission at both receptor types by allowing acetylcholine to accumulate.

Correct Answer

D — Epinephrine activates alpha-1 receptors to reverse vasodilation and restore blood pressure, beta-2 receptors to reverse bronchospasm, and beta-1 receptors to support cardiac output

Rationale

Anaphylaxis involves three major life-threatening components: systemic vasodilation producing hypotension, bronchospasm threatening airway patency, and reduced cardiac output from distributive shock. Epinephrine addresses all three simultaneously because it activates all adrenergic receptor subtypes. Alpha-1 activation on vascular smooth muscle produces vasoconstriction, raising blood pressure and reducing tissue edema. Beta-2 activation on bronchial smooth muscle produces bronchodilation, restoring airway flow. Beta-1 activation on the heart increases rate and contractility, supporting perfusion. No other single drug addresses all three components through a single injection. Epinephrine does not block histamine receptors, does not activate muscarinic receptors, and its activity extends well beyond beta-2.

Correct Answer

B — Large doses are needed to competitively overcome the massive acetylcholine accumulation at muscarinic receptors; skeletal muscle fasciculations and weakness from nicotinic receptor excess require pralidoxime, not atropine

Rationale

Organophosphate poisoning causes irreversible acetylcholinesterase inhibition, allowing acetylcholine to accumulate at all cholinergic synapses. At muscarinic receptors, this produces the SLUDGE syndrome — salivation, lacrimation, urination, defecation, gastrointestinal cramps, and emesis — along with bradycardia and bronchospasm. Atropine competes with the massively elevated acetylcholine for muscarinic receptor occupancy, so doses far exceeding standard clinical use are required. However, atropine does not block nicotinic receptors, so it does not reverse the nicotinic effects of acetylcholine excess — skeletal muscle fasciculations, weakness, and potential respiratory paralysis. Pralidoxime reactivates acetylcholinesterase if given before covalent aging occurs, addressing both muscarinic and nicotinic excess at the source. Organophosphates do not destroy atropine and do not upregulate muscarinic receptors.

Correct Answer

A — Labetalol combines alpha-1 receptor blockade, which reduces peripheral vascular resistance, with non-selective beta receptor blockade, which reduces heart rate and cardiac contractility

Rationale

Labetalol is a combined alpha-1 and non-selective beta adrenergic receptor antagonist. Alpha-1 blockade on vascular smooth muscle reduces peripheral resistance, lowering blood pressure. Non-selective beta blockade reduces heart rate and cardiac output. The combination produces effective blood pressure reduction without the reflex tachycardia that can occur with pure vasodilators, because beta-1 blockade blunts the baroreceptor-mediated sympathetic response. In pregnancy, labetalol is favored because it has an established safety record and the dual mechanism avoids large swings in heart rate. Labetalol does not block alpha-2 receptors centrally, does not block muscarinic receptors, and is not cardioselective.

Correct Answer

C — Each dose of ephedrine releases norepinephrine from sympathetic terminals; with repeated dosing the terminals become depleted of norepinephrine, leaving less available for subsequent doses to release

Rationale

Ephedrine is an indirect-acting sympathomimetic that produces its effects by entering sympathetic nerve terminals and promoting norepinephrine release. Each administration empties a portion of the norepinephrine stored in vesicles, and if doses are given before terminals can replenish their stores through new synthesis and reuptake, subsequent doses find progressively less norepinephrine available for release. This store depletion is the mechanism of tachyphylaxis with indirect sympathomimetics. Receptor downregulation can occur with chronic direct agonist use but develops over hours to days and does not account for the rapid tachyphylaxis seen with repeated ephedrine dosing at short intervals. Ephedrine does not induce its own metabolism and does not stimulate parasympathetic acetylcholine release.

Correct Answer

D — Phenoxybenzamine binds irreversibly to alpha receptors, so the massive catecholamine surge released during tumor manipulation cannot overcome its blockade, whereas phentolamine's competitive blockade can be displaced by high catecholamine concentrations

Rationale

The key distinction between phentolamine and phenoxybenzamine is reversibility of receptor binding. Phentolamine is a competitive antagonist — it can be displaced from the receptor by sufficiently high concentrations of the competing agonist. During pheochromocytoma surgery, physical manipulation of the tumor can release massive quantities of catecholamines that overwhelm competitive alpha blockade, causing potentially fatal hypertensive crisis. Phenoxybenzamine forms a covalent bond with alpha receptors, producing irreversible blockade that cannot be overcome regardless of catecholamine concentration. This irreversibility is precisely what makes it suitable for preoperative preparation. Phenoxybenzamine is non-selective, not selective for alpha-1. Phentolamine does not block beta receptors.

Correct Answer

B — Glucagon activates its own distinct Gs-coupled receptor on cardiac cells, increasing cyclic adenosine monophosphate and stimulating heart rate and contractility independently of beta receptors

Rationale

The glucagon receptor is a distinct G-protein-coupled receptor that couples to Gs, activating adenylyl cyclase and increasing cyclic adenosine monophosphate in cardiac cells. Because the glucagon receptor is entirely separate from beta adrenergic receptors, it can stimulate the same downstream signaling cascade even when beta-1 receptors are completely blocked. This receptor bypass is the pharmacological rationale for glucagon in beta-blocker overdose — it restores positive chronotropy and inotropy through an alternative entry point into the Gs-cyclic adenosine monophosphate pathway. Glucagon does not displace beta-blockers from beta receptors, does not activate muscarinic receptors, and does not inhibit phosphodiesterase.

Correct Answer

A — Physostigmine is a tertiary amine that crosses the blood-brain barrier and can reverse central anticholinergic toxidrome; neostigmine is a quaternary ammonium compound that does not cross the blood-brain barrier and is used for peripheral neuromuscular reversal

Rationale

The critical pharmacokinetic difference between physostigmine and neostigmine is blood-brain barrier penetration. Physostigmine is a tertiary amine — it is lipid-soluble and crosses the blood-brain barrier, allowing it to inhibit acetylcholinesterase in the central nervous system. This makes physostigmine the treatment of choice for severe central anticholinergic toxidrome — the confusion, agitation, and delirium caused by drugs such as atropine, antihistamines, and tricyclic antidepressants. Neostigmine is a quaternary ammonium compound — it carries a permanent positive charge and cannot cross the blood-brain barrier. It is therefore confined to peripheral effects and is used to reverse non-depolarizing neuromuscular blockade after surgery. Both drugs inhibit acetylcholinesterase at all cholinergic synapses they can reach; neither is selective for muscarinic or nicotinic sites, and both are reversible inhibitors.

Correct Answer

C — Rocuronium causes competitive blockade at the neuromuscular junction that can be overcome by raising acetylcholine levels with neostigmine; succinylcholine causes depolarizing blockade, and raising acetylcholine would prolong rather than reverse the paralysis

Rationale

Rocuronium is a non-depolarizing neuromuscular blocker — it competitively blocks nicotinic N-M receptors without activating them. Neostigmine inhibits acetylcholinesterase, raising acetylcholine concentrations at the neuromuscular junction. The increased acetylcholine competes with rocuronium for receptor occupancy and gradually displaces it, restoring neuromuscular transmission. Succinylcholine works by an entirely different mechanism — it activates and then desensitizes the N-M receptor, producing depolarizing blockade. Adding more acetylcholine by giving neostigmine would not help and could worsen succinylcholine paralysis by further stimulating the already depolarized endplate. Succinylcholine is terminated by pseudocholinesterase, and its prolonged action in patients with low pseudocholinesterase activity must simply be managed with ventilatory support until the drug is metabolized.

Correct Answer

D — Propranolol blocks beta-2 receptors in bronchial smooth muscle, removing endogenous bronchodilatory tone and opposing albuterol's mechanism; a cardioselective beta-1 antagonist such as metoprolol carries lower risk in this patient

Rationale

Propranolol is a non-selective beta antagonist that blocks both beta-1 receptors in the heart and beta-2 receptors in bronchial smooth muscle. Beta-2 receptor activation by endogenous epinephrine normally maintains a degree of bronchodilatory tone in the airway. Blocking these receptors removes this tone and directly opposes the mechanism by which albuterol works, explaining the patient's partial inhaler response. In patients with asthma or reactive airway disease, non-selective beta-blockers are contraindicated. If a beta-blocker is needed for migraine prevention, a cardioselective beta-1 antagonist such as metoprolol carries substantially lower risk because at therapeutic doses it has much less effect on airway beta-2 receptors. Propranolol does not activate muscarinic receptors, does not block alpha-1 receptors, and does not affect acetylcholinesterase.

Correct Answer

B — Beta blockade removes the vasodilatory influence of beta-2 receptor activation on blood vessels, leaving alpha-1-mediated vasoconstriction unopposed by the excess tumor catecholamines, which can precipitate paradoxical severe hypertension

Rationale

Pheochromocytomas secrete large amounts of catecholamines, predominantly epinephrine and norepinephrine. Epinephrine activates both alpha-1 receptors, causing vasoconstriction, and beta-2 receptors, causing vasodilation. These opposing effects partially balance each other, limiting the severity of hypertension. If a beta-blocker is given without prior alpha blockade, beta-2 mediated vasodilation is removed while alpha-1 mediated vasoconstriction remains fully active and unopposed. The result is a paradoxical worsening of hypertension that can be severe and life-threatening. Establishing alpha blockade first with phenoxybenzamine neutralizes the vasoconstrictive component before the vasodilatory component is removed by the beta-blocker. Beta-blockers do not interact with alpha receptors and do not directly stimulate catecholamine secretion from the tumor.

Correct Answer

A — Succinylcholine is normally metabolized rapidly by pseudocholinesterase in the plasma; with reduced enzyme activity, the drug persists in the circulation and continues to depolarize and block the neuromuscular junction

Rationale

Succinylcholine's brief normal duration of action — approximately five to ten minutes — depends entirely on rapid hydrolysis by pseudocholinesterase (also called plasma cholinesterase or butyrylcholinesterase) circulating in the blood. This enzyme cleaves succinylcholine into succinylmonocholine and then succinate and choline, terminating its effect before it can be removed from the neuromuscular junction by diffusion and renal excretion. Patients with genetically reduced pseudocholinesterase activity, or with acquired deficiency from liver disease, pregnancy, or certain drugs, cannot metabolize succinylcholine at normal rates. The drug persists in the plasma, continues to reach the neuromuscular junction, and maintains depolarizing blockade for hours. Management requires continued ventilatory support — there is no pharmacological reversal agent for succinylcholine. Acetylcholinesterase at the neuromuscular junction does not metabolize succinylcholine, and succinylcholine does not convert to a non-depolarizing agent or inhibit acetylcholinesterase.

Correct Answer

C — Pyridostigmine inhibits acetylcholinesterase throughout the body, allowing acetylcholine to accumulate at muscarinic receptors in glands, gut, and bladder; atropine can block these muscarinic side effects while preserving the nicotinic benefit at the neuromuscular junction

Rationale

Pyridostigmine treats myasthenia gravis by inhibiting acetylcholinesterase at the neuromuscular junction, increasing acetylcholine availability at nicotinic N-M receptors on the motor endplate. However, acetylcholinesterase inhibition occurs throughout the body, and acetylcholine also accumulates at muscarinic receptors in the gut, bladder, and glands. The resulting symptoms — salivation, lacrimation, urination, diarrhea, gastrointestinal cramps, and emesis — constitute the SLUDGE syndrome. Because atropine blocks muscarinic receptors without affecting nicotinic receptors, it can suppress these parasympathetic side effects while leaving the therapeutic nicotinic effect at the neuromuscular junction intact. Pyridostigmine is a quaternary ammonium compound and does not cross the blood-brain barrier, so physostigmine is not indicated here. Pyridostigmine does not directly activate muscarinic receptors and does not block nicotinic receptors.